CD44 and neoplasm: Surface modifications, such as hyaluronic acid or antibodies targeting CD44 or EGFR, enable active tumor targeting, while stimulus-responsive nanoplatforms (e.g., pH- or GSH-sensitive) ensure controlled release of Sonosensitizers and immunostimulants within the TME (14).